2021 Fiscal Year Final Research Report
Development of the new treatment for docetaxel resistant CRPC
| Project/Area Number |
19K18593
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
Kato Minoru 大阪市立大学, 大学院医学研究科, 講師 (30711684)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 前立腺癌 / アンドロゲン受容体 |
|---|
| Outline of Final Research Achievements |
In this study, we evaluated the association between AR-V7 expression and taxane resistance. First, LNCaP95-DR cells were established from LNCaP95, a CRPC cell line that constantly expresses AR-V7 and is resistant to enzalutamide, and have acquired docetaxel resistance. EPI-002 inhibited cell proliferation of LNCaP95-DR as well as that of the parental strain LNCaP95, suggesting that AR-N-terminus-targeted drugs may be an effective treatment for CRPCs that are both enzalutamide-resistant and taxane-resistant.
|
| Free Research Field |
泌尿器癌
|
| Academic Significance and Societal Importance of the Research Achievements |
これまで去勢抵抗性前立腺癌に対して有効性を示す薬剤 (エンザルタミド、アビラテロン、アパルタミド、ダロルタミド、ドセタキセル)がホルモン感受性のある転移性前立腺癌の治療に前倒し使用できるようになり、これまで以上に去勢抵抗性前立腺癌の治療は複雑化しつつある。初回治療の治療選択肢が増えた一方で、二次治療以降の治療薬は限定的であるため、新規治療薬の開発は非常に重要であることは言うまでもないが、本研究はこれまでに臨床応用されていない薬剤の未知の作用機序を明らかにした点で意義が大きいと考えられる。
|
